Recent discussions highlight concerns over potential health risks linked to phthalates in soft gelatin capsules. A 2021 study suggested a correlation between phthalate plasticizers and increased heart attack risk, although causation remains unproven. Catalent denies any use of phthalates in its softgel products, indicating that approved alternatives are used instead. The FDA database does not list phthalates in softgel capsules, reinforcing this claim. The controversy centers on distinguishing between high and low molecular weight phthalates, with the latter generally considered safer for medicinal use.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.